Welcome to Multibagg AI
Log in to access personalized features
Discovery themes featuring this stockBearish
3
Neutral
4
Bullish
7
Bearish
23
Neutral
4
Bullish
19
Bearish
20
Neutral
0
Bullish
12
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Akums Drugs and Pharmaceuticals Limited is an integrated pharmaceutical CDMO and formulations company that manufactures finished dosage forms, sterile injectables and APIs while also marketing branded formulations through its Akumentis business; the company combines domestic branded sales with a CDMO focus, exports and an API vertical across multiple accredited manufacturing sites.
Q3 FY26 showed strong operating momentum for Akums: consolidated total income of INR1,194 crore (+16.5% YoY), operating revenue of INR1,160 crore (+14.8% YoY), Adj. EBITDA of INR147 crore (12.7% margin, +21% YoY) and CDMO contributing roughly 79% of revenues, reflecting successful volume-led growth despite API price pressure.
Akums is advancing two transformational international projects: an EU CDMO contract with an eventual EUR35 million annual run‑rate (Plant 2 EU‑GMP certified; commercial supplies targeted FY28) and a Zambia government supply project with expected Indian‑plant supplies in H1 FY27 and local plant commissioning thereafter.
The API vertical remains under pressure from prolonged soft pricing, but management reports signs of stabilization, portfolio rationalization and cost controls that reduced API losses sequentially; CDMO volumes rose strongly, driving operating leverage and a QoQ uptick in adjusted profitability.
Balance sheet and cash flow strength are notable: cash surplus of INR1,573 crore with operating cash flow of INR1,109.5 crore and free cash flow of INR944.5 crore in the period, enabling Akums to fund capex, regulatory filings and selective inorganic or strategic deployments while implementing SAP S/4HANA for operational efficiency.
Pharmaceuticals & Biotechnology
Pharmaceuticals
8,143 Cr
High Risk
31.9
35.4
0.7
2.5
620.00
410.10
Sales CAGR
Profit CAGR
ROE
ROCE
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Discovery themes featuring this stock
Investor Presentation
Q4 FY26
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Akums Drugs & Pharmaceuticals Ltd (AKUMS) is currently trading at 515.40 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Akums Drugs and Pharmaceuticals Limited is an integrated pharmaceutical CDMO and formulations company that manufactures finished dosage forms, sterile injectables and APIs while also marketing branded formulations through its Akumentis business; the company combines domestic branded sales with a CDMO focus, exports and an API vertical across multiple accredited manufacturing sites. Q3 FY26 showed strong operating momentum for Akums: consolidated total income of INR1,194 crore (+16.5% YoY), operating revenue of INR1,160 crore (+14.8% YoY), Adj. EBITDA of INR147 crore (12.7% margin, +21% YoY) and CDMO contributing roughly 79% of revenues, reflecting successful volume-led growth despite API price pressure. Akums is advancing two transformational international projects: an EU CDMO contract with an eventual EUR35 million annual run‑rate (Plant 2 EU‑GMP certified; commercial supplies targeted FY28) and a Zambia government supply project with expected Indian‑plant supplies in H1 FY27 and local plant commissioning thereafter. The API vertical remains under pressure from prolonged soft pricing, but management reports signs of stabilization, portfolio rationalization and cost controls that reduced API losses sequentially; CDMO volumes rose strongly, driving operating leverage and a QoQ uptick in adjusted profitability. Balance sheet and cash flow strength are notable: cash surplus of INR1,573 crore with operating cash flow of INR1,109.5 crore and free cash flow of INR944.5 crore in the period, enabling Akums to fund capex, regulatory filings and selective inorganic or strategic deployments while implementing SAP S/4HANA for operational efficiency.
Over the past 52 weeks, Akums Drugs & Pharmaceuticals Ltd has traded between a low of ₹410.10 and a high of ₹620.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Akums Drugs & Pharmaceuticals Ltd has a market capitalization of approximately 8,142.78. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Akums Drugs & Pharmaceuticals Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 31.91 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 8,142.78 Cr, Akums Drugs & Pharmaceuticals Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Akums Drugs & Pharmaceuticals Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Akums Drugs & Pharmaceuticals Ltd is 31.91. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Akums Drugs and Pharmaceuticals launched dapagliflozin plus pioglitazone tablets, a combination therapy for the management of type 2 diabetes.
A total dividend of ₹3.00 per share, comprising a ₹1.00 final dividend and a ₹2.00 special dividend for the year ended March 31, 2026.
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
420.00 | 9,359 Cr | 62.37 | 3.84 | 0.10 | 6.35 | 8.41 | 4.29 | ||
5312.00 | 8,775 Cr | 29.90 | 14.16 | 2.36 | 49.51 | 65.17 | 32.81 | ||
515.40 | 8,143 Cr | 31.91 | 2.46 | 0.56 | 7.70 | 10.95 | 4.71 | ||
3380.10 | 8,112 Cr | 19.63 | 9.43 | 3.49 | 42.11 | 52.41 | 25.64 | ||
674.15 | 7,922 Cr | 39.21 | 22.40 | 0.17 | 42.02 | 46.06 | 36.87 | ||
403.05 | 7,458 Cr | 25.40 | 5.94 | 0.28 | 28.06 | 37.35 | 19.22 | ||
603.60 | 7,324 Cr | 43.54 | 8.92 | 0.00 | 20.63 | 23.80 | 17.20 | ||
| Median: 7 Co. | — | 603.60 | 8,112 Cr | 31.91 | 8.92 | 0.28 | 28.06 | 37.35 | 19.22 |
Secretarial compliance
Akums Drugs & Pharmaceuticals submitted its Annual Secretarial Compliance Report for the year ended 31-Mar-2026 to NSE & BSE, prepared by SPG & Associates, noting compliance with SEBI LODR provisions with exceptions detailed in Annexure-A.
Operational Disruption
Akums reports industry-wide labour unrest in Uttarakhand disrupted some Haridwar manufacturing sites; over 70% of operations resumed from 16 May 2026, with production loss covered under industrial insurance and claims to be lodged.
Operations Disruption Update
Akums reports industry-wide labour unrest in Uttarakhand disrupted some Haridwar manufacturing sites but over 70% of operations resumed from 16 May 2026; no property damage, production-loss covered by industrial insurance, financial impact being ascertained.
Results Publication
Akums Drugs & Pharmaceuticals published newspaper advertisements (15‑May‑2026) with QR links to Board‑approved unaudited standalone & consolidated results for quarter ended 31‑Mar‑2026 and audited FY2026 results (approved 14‑May‑2026).
Newspaper Publication
Akums Drugs published newspaper advertisements on May 15, 2026 with QR codes linking to Board‑approved unaudited standalone & consolidated Q4 results and audited standalone & consolidated FY results for year ended March 31, 2026.
Investor Presentation
Akums submitted its Q4 & FY26 investor presentation reporting double‑digit CDMO volume growth, improved margins and 44% capacity utilisation; highlights include a €200m European CDMO contract, EU GMP approval, Zambia JV and FY28 supply ramp.
